Advertisement

Cancer Causes & Control

, Volume 6, Issue 2, pp 130–134 | Cite as

Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies (Massachusetts, United States)

  • Bernard L. Harlow
  • Daniel W. Cramer
Research Papers

Data from two population-based case-control studies in the greater metropolitan Boston, MA (USA) were used to assess the association of self-reported use of antidepressants or benzodiazepine tranquilizers and epithelial ovarian cancer. Cases were women between 18 and 80 years of age diagnosed with epithelial ovarian cancer during two time periods: November 1978 through September 1981, and July 1984 through September 1987. Female controls were identified from Massachusetts town books and were frequency-matched to cases by age, race, and precinct of residence. In-person interviews assessed reproductive and medical histories as well as prescription medication use. Prior use of antidepressants or benzodiazepine tranquilizers exceeding one to six months was associated with an increased risk of ovarian cancer (adjusted odds ratio [OR]=2.1, 95% confidence interval [CI]=0.9–4.8, and adjusted OR=1.8, CI=1.0–3.1, respectively). The association was confined primarily to women whose first use occurred before age 50 years (adjusted OR=3.5, CI=1.3–9.2, and adjusted OR=2.7, CI=1.3–5.6, respectively). No association was observed with respect to other non-hormonal medications reported.

Key words

Antidepressants benzodiazepines ovarian neoplasms retrospective studies United States 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tzonou A, Day NE, Trichopoulos D, et al. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol 1984; 20: 1045–52.Google Scholar
  2. 2.
    Grodstein F, Goldman MB, Ryan L, Cramer DW. Self-reported use of pharmaceuticals and primary ovulatory infertility. Epidemiology 1993; 4: 151–6.Google Scholar
  3. 3.
    Cramer DW, Harlow BL. Depression and hypogonadism (Abstract). Am J Epidemiol 1992; 136: 994.Google Scholar
  4. 4.
    Cramer DW, Hutchison GB, Welch WR, Skully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. New Eng J Med 1982; 307: 1047–51.Google Scholar
  5. 5.
    Cramer DW, Harlow BL, Willett WC, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989; 2: 66–71.Google Scholar
  6. 6.
    Rothman KJ. Modern Epidemiology. Boston, MA (USA): Little, Brown, 1986: 177–236.Google Scholar
  7. 7.
    Breslow NE, Day NE, eds. Statistical Methods in Cancer Research, Vol 1. The Analysis of Case-control Studies. Lyon: International Agency for Research on Cancer, 1980; IARC Sci. Pub. No. 32.Google Scholar
  8. 8.
    Friedman GD. Depression, worry, and the incidence of cancer (Letter). Am J Public Health 1990; 80: 1396–7.Google Scholar
  9. 9.
    Friedman GD. An editor comments: Re: Depression, antidepressant medication, and cancer (Letter). Am J Epidemiol 1992; 136: 1415–6.Google Scholar
  10. 10.
    Tzonou A, Polychronopoulou A, Hsieh C-c, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 1993; 55: 408–10.Google Scholar
  11. 11.
    Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136: 1184–203.Google Scholar
  12. 12.
    Farrow DC, Weiss NS, Lyon JL, Daling JR. Association of obesity and ovarian cancer in a case-control study. Am J Epidemiol 1989; 129: 1300–4.Google Scholar
  13. 13.
    Ross CE. Overweight and depression. J Health Soc Behav 1994; 35: 63–79.Google Scholar
  14. 14.
    Weissman M, Bruce ML, Leaf PJ, Florio LP, Holzer C. Affective disorders; In: Robins LN, Regier DA, eds. Psychiatric Disorders in America. New York, NY (USA): The Free Press, 1991.Google Scholar
  15. 15.
    Cramer DW, Welch WR. Determinants of ovarian cancer risk II. Inferences regarding pathogenesis. JNCI 1983; 71: 717–21.Google Scholar
  16. 16.
    Feuer G. Drug control of steroid metabolism by the hepatic endoplasmic reticulum. Drug Metab Rev 1983; 14: 1119–44.Google Scholar
  17. 17.
    Attia MA, Aref H. Hepatic microsomal enzyme induction and thyroid function in rats treated with high doses of phenobarbitol and chlorpromazine. Dtsch Tierarztl Wochenschr 1991; 98: 209–13.Google Scholar
  18. 18.
    Biskind MS, Biskind GR. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 1944; 55: 176–9.Google Scholar
  19. 19.
    Brandes LJ, Arron RJ, Bogdanovic RP, et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992; 52: 3796–800.Google Scholar

Copyright information

© Rapid Communications of Oxford Ltd 1995

Authors and Affiliations

  • Bernard L. Harlow
    • 1
  • Daniel W. Cramer
    • 1
  1. 1.Obstetrics and Gynecology Epidemiology Center at Brigham and Women's HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations